Epilepsy Epidiolex denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for epilepsy epidiolex are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Limits Quantities of Epidiolex — and How to Appeal

Epidiolex (cannabidiol) is an FDA-approved anti-seizure medication prescribed for certain severe, treatment-resistant epilepsy syndromes. Cigna's quantity limits for Epidiolex restrict the volume dispensed per coverage period — commonly the amount of oral solution covered per fill or per month. These limits are set by Cigna's internal pharmacy and medical policy, and they may not reflect the individualized dose that the treating neurologist has determined is clinically appropriate for a specific patient. When the prescribed quantity exceeds Cigna's standard limit, a quantity-limit exception or appeal is required.

## Why This Denial Is Appealable

Quantity-limit denials are appealable when the treating neurologist documents a medical justification for the prescribed quantity. Because Epidiolex dosing is individualized based on patient weight and clinical response — refer to the FDA-approved prescribing label for the approved dosing framework — a patient may legitimately require a quantity that exceeds Cigna's default limit. The prescriber's documentation linking the patient's characteristics and clinical response to the prescribed amount is the cornerstone of the appeal.

## Your Federal Appeal Rights

• Internal appeal: ACA §2719 and ERISA §503 entitle you to a full-and-fair internal review. Submit the appeal within the deadline on your denial letter.
• External review: If the internal appeal is denied, you have approximately four months to request independent external review by an IRO with neurology expertise.
• Expedited review: If withholding the full prescribed quantity creates an immediate seizure risk, request expedited review for a 72-hour resolution.

## Documentation to Gather

1. Current prescription and quantity justification: The prescription itself, along with a notation from the prescribing neurologist explaining the clinical rationale for the specific quantity ordered (e.g., patient weight, titration schedule, or inadequate seizure control at lower quantities). 2. FDA prescribing label: Attach the FDA-approved label showing the approved dosing framework and the weight-based or response-based titration guidance — this demonstrates that the prescribed quantity is consistent with FDA-approved use. 3. Seizure frequency documentation: Records showing that seizures remain inadequately controlled, justifying the current prescribed quantity rather than a reduction. 4. Prior quantity history: If the patient was previously covered at the requested quantity without issue, include that dispensing history as evidence of established clinical need. 5. Prescriber medical-necessity letter: A letter from the treating neurologist specifically addressing Cigna's quantity limit, explaining why the standard limit is insufficient for this patient, and citing the FDA label's dosing guidance.

## Criteria-Mapping Structure

Review Cigna's quantity-limit policy for Epidiolex (available in Cigna's pharmacy coverage documents or formulary exception guidelines):

| Quantity-Limit Criterion | Supporting Evidence | |---|---| | Prescribed quantity within FDA-approved dosing range | [FDA label dosing section + prescription] | | Clinical justification for quantity above standard limit | [Neurologist letter with patient-specific rationale] | | Seizure control documentation | [Seizure log or chart summary] | | Prescriber attestation | [Medical-necessity letter from neurologist] |